Women with preterm premature rupture of the membranes do not benefit from weekly progesterone.
OBJECTIVE
We sought to determine if 17-alpha-hydroxyprogesterone (17P) extends gestation vs placebo in women with preterm premature rupture of the membranes (PPROM).


METHODS
Women with vertex presentations with PPROM, 20-30 weeks' gestation, were randomized to receive weekly 17P or placebo in an attempt to prolong the pregnancy. A total of 69 patients (17P, n = 33; placebo, n = 36) were randomized into this study.


RESULTS
Initial cervical dilatation, gestational age at enrollment, and interval to delivery were not different between the 2 groups (P = .914, .424, and .146, respectively). Time of randomization to delivery (P = .250), mode of delivery (relative risk, 1.16; 95% confidence interval, 0.66-2.06), and the neonatal outcome statistics of morbidity (P = .820) and mortality (relative risk, 1.28; 95% confidence interval, 0.59-2.75) were similar between the 2 groups.


CONCLUSIONS
In patients with PPROM, 17P did not extend gestation vs placebo and cannot be recommended for treatment in such women.
Briery
Christian M
CM
Department of Maternal-Fetal Medicine, Willis-Knighton Health Sciences Center, Shreveport, LA, USA.
Veillon
Edward W
EW
Klauser
Chad K
CK
Martin
Rick W
RW
Magann
Everett F
EF
Chauhan
Suneet P
SP
Morrison
John C
JC
D019326:17-alpha-Hydroxyprogesterone / Q000008:administration & dosage*; D000328:Adult; D000465:Algorithms; D004334:Drug Administration Schedule; D005260:Female; D005322:Premature Rupture of Fetal Membranes / Q000188:drug therapy*; D046689:Fetal Mortality; D005865:Gestational Age; D006801:Humans; D007747:Labor Stage, First / Q000187:drug effects / Q000502:physiology; D008922:Mississippi; D011247:Pregnancy; D047928:Premature Birth / Q000517:prevention & control*; D018709:Statistics, Nonparametric; D055815:Young Adult
D019326:17-alpha-Hydroxyprogesterone